Have library access?
IP:3.236.143.154

Abstracts


多重抗藥性結核病(multidrug-resistant tuberculosis)是指罹患至少對最重要的兩種抗結核藥物isoniazid及rifampicin抗藥的結核菌株之結核病。造成多重抗藥性結核病的原因很多,但最常見的原因多爲病人服藥順從性不佳或醫師不適當之治療療程。藉由短程直接觀察療法「都治計畫」(directly observed therapy, short-course; DOTS)的介入,能減少多重抗藥性結核病的產生。而對於多重抗藥性結核病而言,預防永遠是最好的策略。另外藉由「進階都治計劃」(DOTS-Plus)的介入,以期增加多重抗藥性結核病的治癒率。經由建構有效率的結核病防治體系,是預防及治療多重抗藥性結核病的重要策略。

Parallel abstracts


Multidrug-resistant tuberculosis (MDR-TB) is defined by bacillary resistant to at least isoniazid and rifampicin in vitro. Although a great diversity of reasons accounting for MDR-TB, poor treatment adherence of patient or inappropriate prescription of physicians are still the major causes. Implementation of DOTS (directly observed therapy, short-course) could decrease incidence of MDR-TB. For MDR-TB, prevention is best strategy. Besides, implantation of DOTS-plus also could increase cure rate. To build efficacious framework system for managing tuberculosis is an important issue to prevent and treat MDR-TB.

Cited by


陳玫君(2012)。都治關懷員的結核病認知及感染風險調查〔碩士論文,長榮大學〕。華藝線上圖書館。https://doi.org/10.6833/CJCU.2012.00022
郭玟婷(2013)。臺灣結核病照護政策之成效評估:以2008-2011全國免費抗結核二線藥管理控制為例〔碩士論文,國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342/NTU.2013.00364

Read-around